ESC 365 - undefined undefined undefined

Speaker illustration

undefined undefined undefined

Presentations Articles

A randomized, placebo-controlled phase 3 study of plozasiran in patients with familial chylomicronemia syndrome: PALISADE - 1 year open label extension

Event: ESC Congress 2025

Topic: Cardiovascular Disease in Primary Care

Session: Cardiovascular disease in primary care

A randomised, placebo-controlled phase 3 study of plozasiran in patients with familial chylomicronemia syndrome

Event: ESC Congress 2024

Topic: Drug therapy

Session: Smaller trials, trial updates, and other studies on lipid therapy

RNA interference targeting hepatic angiopoietin-like protein 3 results in prolonged reductions in serum triglyceride and non-HDL cholesterol concentrations: first human results with ARO-ANG3

Event: ESC Congress 2023

Topic: Chronic Heart Failure

Session: Nature Medicine: highlights in cardiovascular research

RNAi inhibition of angiopoietin-like protein 3 (ANGPTL3) with ARO-ANG3 mimics the lipid and lipoprotein profile of familial combined hypolipidemia

Event: ESC Congress 2020

Topic: Lipid-Lowering Agents

Session: Novel Approaches to Lipid Lowering Therapy

Factorial effects of evolocumab and atorvastatin on lipoprotein metabolism: the FLOREY stable isotope study

Event: ESC Congress 2016

Topic: CAD and comorbidities

Session: Comorbidities and risk for CAD

RNAi inhibition of angiopoietin-like protein 3 (ANGPTL3) with ARO-ANG3 mimics the lipid and lipoprotein profile of familial combined hypolipidemia

Event: ESC Asia with APSC & AFC 2020

Topic: Lipid-Lowering Agents

Session: Abstract Programme

ESC 365 is supported by

novartis

Explore sponsored resources